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ABSTRACT 
There is an overwhelming amount of evidence that show that DNA methylation patterns 
are altered in cancer. In a normal cell, methylation of CpG-rich islands in regulatory regions of 
genes which confer selective advantage upon cancer cells such as tumor suppressors, adhesion 
molecules, inhibitors of angiogenesis and repair enzymes results in their transcriptional 
silencing. In parallel, these genes are globally less methylated in the tumor cell genomes normal 
counterparts. As compared to regional hypermethylation, the global hypomethylation in cancer 
cells occurs in sparsely distributed CpG sequences, thus making DNA methylation an important 
contributor in setting gene expression programs during development. Evidence from research 
suggests that changes in DNA methylation patterns are involved in human disease through 
altering normal gene expression programming. With respect to genetic changes aberrant DNA 
methylation patterns are potentially reversible raising the hope for DNA methylation based 
therapeutics. This reversal of DNA methylation patterns is accomplished mainly by passive 
mechanisms which include covalent trapping of DNMTs by cytosine base analogues. Removal 
of methyl layer could also be occurred by excision of the 5-methyl cytosine base by DNA 
glycosylase. However, the importance of truly chemically defined direct demethylation on intact 
DNA is mainly in the regulation of gene expression, development and cell growth, hence it 
becomes necessary to know the exact biochemical mechanism and the enzymes involved in it. 
The present study has been carried out keeping this in mind with an objective to study the role of 
demethylation in cancer and investigate certain candidate genes such as methyl-binding proteins 
MBD2 and MBD4 for putative demethylase activity. 
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INTRODUCTION 
DNA methylation and DNA demethylation are two sides of the same coin, representating 
two opposing yet concerted mechanism that form the basis of epigenetic regulation of genome. 
Epigenetic inheritance is defined as information encoded in the genome, other than the DNA 
sequence itself that is heritable during cell division thus representating a critical mechanism that 
allows a remarkably stable propagation of gene activity states over many cell generations. The 
field of epigenetics has been becoming important in the recent years, owing largely to the 
knowledge that epigenetic inheritance is essential for development and critical cellular processes 
such as gene transcription, differentiation, and protection against viral genomes. Epigenetic 
inheritance might explain unusual phenomena such as position effect variegation in flies, 
telomere and mating-type silencing in yeast, and transgene induced gene silencing in plants and 
animals.  Epigenetic mechanisms are adapted for specific cellular memory function not only 
during development but also during life-time. Epigenetic information that can be considered as 
heritable are classified into three distinct types: DNA methylation, Histone modifications, and 
non-coding RNAi mediated gene silencing.  
However different epigenetic mechanisms tend to cross-influence and reinforce each 
other in the regulation of cellular response to environmental stimuli as well as endogenous 
signals. This concerted action of myriad epigenetic events is essential for the homeostatic 
orchestration of diverse cellular processes. Epigenetic information that control gene expression 
are transmitted to daughter cells independently of the DNA sequence. These metastable patterns 
however sometimes become abnormal during fetal development, thereby predisposing 
individuals to paediatric cancers, and can also change during normal ageing to contribute 
towards common cancer risk in adults. One of the most remarkable developments in the field of 
epigenetics is the emerging proofs that aberrant epigenetic states and genetic changes in cancer 
are linked and that aberrant epigenetic states may predispose to genetic events during tumor 
development and progression. Epigenetic and genetic mechanisms may thus work in tandem to 
silence the transcription of key cellular genes and destabilize the genome, leading to malignant 
transformation and tumor development. 
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Proliferation and propagation of cancer involves coordinated changes in gene expression 
program of multiple genes. Since genomic expression is regulated by the epigenome it stands to 
reason that changes in the status of epigenome plays a critical role in oncogenesis. One important 
hallmark of cancer is a paradoxical aberration in the patterns of established DNA methylation 
where global loss of DNA methylation coexists concomitantly with regional hypermethylation of 
certain genes Since cancer involves a concerted activation and inactivation of genes, hence both 
gene-specific hypermethylation, which suppress tumor genesis by targeting the silencing of 
genes, and genome wide global hypomethylation that probably targets activation of genes, take 
place in cancer. Both these processes occur independently as well as simultaneously to target 
different genetic programs at different stages in tumor genesis. This targeting of different sets of 
genes with opposing roles in cellular transformation confers a selective advantage upon cancer 
cells which are required for different stages of the transformation process. 
Over recent years there has been remarkable research to elucidate the nature and role of 
the mechanisms involved in CpG promoter hypermethylation during carcinogenesis, however, 
the mechanism behind one of the earliest epigenetic observations in cancer, genome-wide 
hypomethylation, remains unclear. The enzymes and cofactors associated with DNA methylation 
reactions can be explained in terms of its chemical thermodynamics. However, the mechanism of 
demethylation, the candidate enzyme(s) exhibiting direct demethylase activity, and associated 
cofactors are not firmly established. In recent years the methyl-binding domain proteins MBD2 
and MBD4 has been shown to have putative demethylase activity, but concrete evidence 
regarding this hypothesis has not been proved. Keeping this fact in mind, the present work has 
been carried out to analysize the expression levels of MBD2 and MBD4 in normal and cancer 
tissues and compare their expression with GADD45 which has established demethylase activity 
in Zebra fish. 
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REVIEW OF LITERATURE 
1. DNA Demethylation: 
DNA demethylation is the removal of methyl groups from methylated cytosine bases of 
DNA. It is the earliest observed epigenetic mechanism which represents one of the most 
fundamental epigenetic phenomena to control the developmental programming of a cell through 
a concerted regulation of cell growth, proliferation and propagation alongside DNA methylation 
(Patra et al., 2003). Over recent years there has been remarkable research to elucidate the nature 
and role of the mechanisms involved in CpG promoter hypomethylation during normal 
development as well carcinogenesis. The prevailing view is divided between the hypotheses that 
hypomethylation is either responsible for initiation of cancer-causing aberration or that it is a 
passive inconsequential side effect of carcinogenesis (Wild and Flanagan, 2010). Recent 
discoveries in the area of gene–body methylation, fast cyclic methylation of hormone dependent 
genes such as estrogen receptors and candidate proteins involved in DNA demethylation have 
brought the role of hypomethylation and the mechanism behind it into greater focus.  
2. The Many Functions of DNA Demethylation: 
DNA demethylation plays a vital and evolutionarily significant role in normal 
development and growth of an individual, both in animals and plants. 
 
2.1. Role of DNA demethylation in Mammals: 
There is extensive proof of the importance of global and gene-specific DNA 
demethylation in normal mammalian development (Zhu, 2009). Such examples include: 
 
 Early development: 
Rapid demethylation of the male pronucleus occurs in the zygote of mouse, human, pig, 
rat, and bovine pre-implantation embryos (Zhu, 2009). Demethylation is presumably 
important for reorganizing the epigenetic marks of the paternal genome in order to 
establish paternal-specific developmental programs during early embryogenesis.  
 Reprogramming during gametogenesis and cloning:  
Genome-wide demethylation also occurs in primordial germ cells to erase the parental 
imprints and restore totipotency. The reprogramming of the totipotency regulator gene  
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Oct4 is mediated by active promoter demethylation. In addition to embryonic stem cells 
and oocytes having the capacity to demethylate and reprogram other nuclei, 
differentiated mesodermal somatic cells also have been shown to confer gene-specific 
active DNA demethylation in stable heterokaryons (Ehrlich, 2002). 
 
    Memory formation and neurogenesis:   
DNA methylation is involved in the process of inactivation of the memory suppressor 
gene PP1, whereas demethylation is associated with the activation of the memory 
promoting gene reelin. The expression of BDNF (brain-derived neurotrophic factor) and 
FGF-1 (fibroblast growth factor-1) genes is critical for proper adult neurogenesis (Zhu, 
2009). Demethylation in the promoter regions of BDNF and FGF-1 induced by 
GADD45b (DNA-damage-inducible protein 45 beta), promotes adult neurogenesis. 
Reducing the expression of Gadd45b or other proteins involved in demethylation causes 
the loss of neurons because of hypermethylation and consequent transcriptional 
silencing of genes required for neurogenesis. 
 Immune response: 
     Concerted regulation of DNA methylation and demethylation appears to be an important 
factor in the epigenetic control in the immune response. The cytokines IL-2 and IFN-γ 
are critical for the function of CD8 T cells (Ehrlich, 2002). Upon re-encounter with 
antigens after an infection, the IL-2 and IFN-γ promoters are actively demethylated 
resulting in rapid cytokine production in memory CD8 T cells. 
  
2.2. Role of DNA demethylation in Plants: 
DNA demethylation mechanism in plants plays a diverse role in genome regulation and 
plant development. The different functions of DNA demethylation include: 
 
 Prevention of transcriptional silencing of transgenes and endogenous genes: 
In plants, siRNAs can trigger cytosine methylation and consequent transcriptional 
silencing of    homologous DNA. When a transgene or endogenous gene promoter  
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generates siRNAs, the promoter is silenced by RNA-directed DNA methylation (Zhu, 
2009). The ROS1 (repressor of silencing 1) gene, which encodes a 5
me
C DNA 
glycosylase or demethylase, that maintains the expression of a transgene and its 
homologous endogenous gene. In the absence of ROS1 activity, the homologous genes 
are targets of RNA-directed DNA methylation and become heavily methylated and 
silenced transcriptionally. This study provided evidence that demethylation prevents the 
spreading of DNA methylation from repetitive sequences and thus protects the genes 
from deleterious methylation.  
 
 Regulation of imprinting: 
In Arabidopsis, DNA demethylation is critical for activating the expression of the 
maternal allele of imprinted genes such as FWA (flowering wageningen), the polycomb 
group genes MEA (MEDEA) and FIS2 (fertilization independent seed 2) and the C-
terminal domain of poly (A)-binding protein MPC (maternally expressed PAB C-
terminal). For these imprinted plant genes, the methylated inactive state is the default 
state, and demethylation and consequent expression take place only in the central cell of 
the female gametophyte and the endosperm where an active demethylase is expressed. In 
the Arabidopsis DNA demethylase mutant dme, the imprinted MEA and FWA genes are 
not demethylated and the genes remain silent in the endosperm, which results in 
impaired seed development. 
 
 Regulation of transposons: 
DNA demethylation is important for keeping transposons in a dynamic state so that they 
are not completely silenced. In rice, a ROS1-like 5
me
C DNA glycosylase/DNA 
demethylase is important for maintaining the expression and promoting the transposition 
of the retrotransposons Tos17. Transposons and other repetitive sequences make up the 
large portions of plant genomes, and play important roles in shaping genome structure 
and in evolution by promoting genetic variability through transposition (Zhu, 2009). The 
dynamic control of transposons by both methylation and demethylation may keep the 
plant epigenome plastic so that the plant can respond efficiently to environmental 
challenges during adaptation. 
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 Plant responses to biotic and abiotic stresses: 
Global DNA methylation is reduced to a great extent in Arabidopsis plants infected 
with the bacterial pathogen Pseudomonas syringae. This change occurs in the absence 
of DNA replication, which suggests that it involves a demethylation mechanism. In 
tobacco plants, DNA methylation is rapidly reduced in the coding region of a 
glycerophosphodiesterase like gene one hour after treatment with aluminium, NaCl, 
cold, or oxidative stress which correlates with stress induction of the 
glycerophosphodiesterase-like gene. 
 
3. DNA demethylation and Cancer: 
Changes in human DNA methylation patterns are a important hallmark of cancer 
development and progression and plays a potential role in other conditions such as 
atherosclerosis and autoimmune diseases (e.g., multiple sclerosis and lupus). The cancer genome 
has been found to be frequently characterized by hypermethylation of specific genes 
concurrently with an overall decrease in the level of 5 methyl cytosine (Wilson et al., 2007). This 
hypomethylation of the genome largely affects the intergenic and intronic regions of the DNA, 
particularly repeat sequences and transposable elements, and is believed to result in 
chromosomal instability and increased mutation events. 
3.1. Characteristics of Genome Wide Hypomethylation in Cancer: 
 Genome wide hypomethylation involves decrease in the overall genomic methyl-cytosine 
content from approximately 4% in normal tissues to 2–3% in cancer tissues (Wilson et al., 
2007). This decrease was first observed in a number of studies in 1983, in lung and colon 
carcinomas compared to adjacent normal tissue and in various malignancies compared to 
various postnatal tissues, demonstrating that overall genomic methyl-cytosine levels were 
lower in cancer tissues (Wild and Flanagan, 2010) (Fig 1). However, the overall levels of 
hypomethylation vary widely both within and between cancer types (Wilson et al., 2007), for 
example in colorectal cancer there is an average reduction of 10–30% total methylation 
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levels whereas in solid tumors like breast cancer there is reduction of up to 50% in 5 
me
C 
content. 
 Global hypomethylation appears to play a role in initiation of malignancy in case of colon 
and breast cancer as well as chronic lymphocytic leukemia (Wilson et al., 2007).  
 The relative timing of global demethylation and its role during cancer initiation and 
progression may differ between cancer types, for example in hepatocellular carcinoma the 
degree of hypomethylation increases with stage or histological grade (Wilson et al., 2007).  
 While a loss of methylation is commonly associated with cancer development or progression 
(Fig 2), a critical level of demethylation is not associated with a particular stage of disease. 
For example, although DNA from an individual's cancer may be less methylated than its 
matched normal DNA, the normal tissue DNA for another individual may be even less 
methylated than that of the diseased tissue (Wilson et al., 2007). 
 
 
 
 
 
 
 
 
 
 
    Fig.1. The figure showing published reports of DNA hypomethylation in cancer. Forty-one 
studies investigating genomic hypomethylation in cancer tissues compared to matched 
normal tissues show an overall decrease in all cancer tissues (n=1151 samples), 
decrease in only some cancer tissues (n=386 samples) or show no change in cancer 
tissues compared to match normal tissues (n=160 samples) (Wild and Flanagan, 2010). 
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Fig 2.The figure shows the potential causes and subsequent consequences of DNA       
demethylation cancer (Wilson et al., 2007). 
 
3.2. Where Does Hypomethylation Occur in the Cancer Genome? 
The genomic region where methylation is most frequently lost remains a subject of 
interest and investigation. Much of the effects of global DNA hypomethylation are thought to 
occur through the activation of the normally dormant transposons and endogenous retroviruses 
present in the human genome (Patra and Bettuzzi, 2009). The transcriptional reactivation of the 
strong promoters associated with these elements might globally alter transcription factor levels 
and modify the expression of critical growth regulatory genes regulated by them (Wilson et al., 
2007). The hypomethylation of these sequences might result in further genomic mutations and 
anomalous chromosomal recombination eventuating in the unraveling of the packed chromatin 
and subsequent genomic instability. A study of methylation conducted in randomly fragmented 
DNA from human gastric adenocarcinoma demonstrated that hypomethylation was frequently 
lost in highly repetitive, moderately repetitive and single copy DNA sequences across the 
genome (Wild and Flanagan, 2010). The examples include: 
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 Simple DNA repeats-satellite DNA: 
Hypomethylation of the Sat2 and Satα has been observed in both the genetic ICF 
(Immunodeficiency, Centromeric region instability and Facial anomalies) Syndrome and 
cancers including Wilms tumor, ovarian and breast cancer. Hypomethylation of SatR-1 is 
seen in breast cancer and extensive demethylation of the D4Z4 repeats results in 
facioscapulohumeral muscular dystrophy and ICF syndrome. The DNA repeat NBL2 is 
hypomethylated in neuroblastomas and hepatocellular cancers (Wilson et al., 2007). 
 
 Transposable elements: 
The demethylation of HERV-Ks is seen in germ cell tumors and cancers of the ovary, 
testicles and bladder where its hypomethylation increases with malignancy. Expression of 
HERV- K (Human endogenous retrovirus K) transcripts has also been found in other 
diseases including multiple sclerosis, schizophrenia and cancer cell lines. LINE (Long 
Interspersed Nuclear Element 1, a 6-kb interspersed DNA repeat which makes up around  
15% of the human genome) hypomethylation occurs early in cancer initiation, notably in 
cancers of the colon and prostate (Wilson et al., 2007).  
 
 Individual gene sequences: 
Single copy sequences present in the genome also exhibit hypomethylation in a range of 
cancers, e.g. cancers of the colon, pancreas and the breast which is often associated with 
increased expression of that gene (Wild and Flanagan, 2010). The genes affected by 
hypomethylation includes growth regulatory genes, enzymes, developmentally critical 
genes and tissue specific genes such as germ cell-specific tumor antigen genes, the 
MAGE, BAGE, LAGE and GAGE gene families (Wilson et al., 2007). Examples 
include: 
 The abnormal expression of oncogenes due to cancer-linked hypomethylation 
such as R-Ras has also been shown. 
 There is a strong association of CDH3 promoter demethylation and P-
Cadherin expression in invasiveness in breast cancer. 
 Cyclin D2 activation is associated with Stage III and IV gastric cancer.  
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 Activation of synuclein γ is associated with progression and metastatic potential 
in a range of solid tumors. 
 Maspin expression in colorectal cancer is associated with microsatellite 
unstable tumors.  
 Promoter hypomethylation and expression of the perforin gene results in 
initiation of active Lupus. 
  IGF2 loss of imprinting is seen in colorectal cancer. 
 Other examples include hypomethylation of γ-globin gene in breast and colon 
adenocarcinomas, MN/CA9 in renal cell carcinomas and c-MYC in colorectal 
cancer and hepatocellular carcinomas. 
 
3.3. Evidence for Involvement of Global Demethylation in Cancer: 
The recent focus on hypermethylation of tumor suppressor genes in cancer has turned 
interest away from one of the most remarkable and consistent changes in pattern of DNA 
methylation in cancer i.e. global hypomethylation (Patra and Bettuzzi, 2009). Three lines of 
evidence associate a general reduction in genomic DNA methylation and cancer (Szyf, 2003).  
 The first line of evidence is correlative. A large number of studies in different kinds of 
tumors show that DNA from tumors is hypomethylated when compared with DNA 
prepared from normal tissues (Patra and Bettuzzi, 2009). Hypomethylation is 
heterogeneous i.e. the same satellite sequence might be hypomethylated in some but not 
in all tumors of the same class. The global and heterogeneous nature of these changes 
suggests that that there is major defect in the general DNA methylation machinery in 
tumor cells that result in stochastic changes in DNA methylation in different tumor cells.  
 
 The second line of support comes from epidemiological, clinical and pharmacological 
data showing a causal relation between hypomethylation and cancer from the modulation 
of dietary methyl intake in rodents (Szyf, 2003). These studies suggested that diets with 
high methyl content had a protective effect against cancer in animals, whereas 
hypomethylating diets promoted carcinogenesis. Also low folate intake found to be 
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associated with high alcohol consumption might increase the risk of colorectal cancer. 
Folate is required for the synthesis of tetrahydrofolate a cofactor required for synthesis of 
methionine, which is the precursor of SAM the methyl donor in DNA methylation 
reactions. High alcohol intake reduces SAM concentrations in the liver. To summarize, 
the dietary data supported the model that global hypomethylation can promote cancer. 
 
 Third, early experiments have shown that 5-azaC treatment can enhance the metastatic 
potential of tumor cell lines (Szyf, 2003). These data indicate that hypomethylation of 
DNA might cause induction of genes that promote the invasive capacity of tumors as well 
as promote formation of new tumors (Patra and Bettuzzi, 2009). 
 
3.4. When Does Hypomethylation Occur During Carcinogenesis? 
The occurrence of genomic DNA hypomethylation and its relationship with CpG island 
promoter hypermethylation in cancer is very important for determining its mechanism and its 
significance in carcinogenesis. Studies by Ehrlich et al. in a number of systems including 
colorectal, urothelial, prostate, ovarian and gastric cancers as well as Wilms tumors and non-
Hodgkin's lymphoma have shown that gene-specific hypermethylation and global 
hypomethylation are independent processes—that is the presence or level of global 
hypomethylation does not alter the likelihood of CpG island hypermethylation, and they are 
unlikely to be causally related. DNA hypomethylation in most cancers including some benign 
tumors is believed to constitute an early event in transformation (Wild and Flanagan, 2010). In 
different cancers, the relative timing of occurrence of global and repeat sequence 
hypomethylation and hypermethylation of individual CpG islands can vary. In colorectal cancer 
hypomethylation is evident in early stage diseases while LINE demethylation increases with 
tumor stage. Differences in timing in different cancer types further signifies  that different 
processes underline common CpG island hypermethylation and demethylation of repeat 
sequences associated with global hypomethylation (Wilson et al., 2007). 
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3.5. Possible Mechanisms by which Hypomethylation Promotes Neoplastic 
Transformation: 
3.5.1. Transcriptional activation of oncogenes: 
Global hypomethylation of genomic DNA in the regulatory sequences is observed in 
numerous tumor cells and is responsible for transcriptional activation and over expression of 
proto-oncogene, retrotransposons, growth factors and genes which via their protein products are 
involved in genomic instability and malignant cell proliferation, invasion, and metastasis 
(Luczak and Jagodzinski, 2006). For example: 
 There is report of hypomethylation of c-myc and Ha-ras oncogenes in human tumor 
samples from colonic adenocarcinoma and small cell lung carcinoma relative to adjacent 
normal tissue as well as other oncogenes (Patra and Bettuzzi, 2009). 
 
 Expression of prometastatic tumor genes is induced by DNA hypomethylation. Protein 
products of these genes promote movement of single malignant cells through the 
extracellular matrix to lymphatic or blood capillaries (Luczak and Jagodzinski, 2006). 
These genes include urokinase type plasminogen activator (PLAU), Heparanases and 
calcium binding protein (S100A4).  
 Advanced stage tumors produce proteases that are involved in degradation of the 
extracellular matrix components and promote metastasis of malignant cells. The 
most common protease involved is the PLAU enzyme. This protease is highly 
expressed in metastatic cancers of breast, prostate and other organs and is required 
for invasiveness. PLAU promoter is methylated in breast cancer MCF-7 cells and in 
noninvasive breast tumor cells (Luczak and Jagodzinski, 2006). The treatment of 
breast cancer MCF-7 cells with the DNMT inhibitor resulted in production of PLAU 
protease and increase in invasiveness of MCF-7 cells in mouse model. Treatment of 
breast cancer cells with the DNA methylation inhibitor 5-aza-CdR resulted in 
demethylation and activation of PLAU as well as increased invasiveness in vitro and 
metastasis in vivo. 
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  Heparanases are released from malignant cells and degrade heparan sulfate 
proteoglycans of the extracellular matrix.  
 S100A4 protein regulates production of matrix-degrading enzymes responsible for 
remodeling of the extracellular matrix and increase in tumor cell proliferation and 
motility. 
 Expression of Testis-cancer specific antigens such as members of the MAGE family 
correlates with aggressive and invasive breast cancer. 
 Insulin-like growth factor 2 (IGF2) is a growth factor that stimulates malignant cell 
proliferation. In nonmalignant cells, IGF2 is transcribed only from one allele, while 
the second one is imprinted and transcriptionally inactive. Hypomethylation of DNA 
in tumor genome results in a loss of imprinting of the second allele and increased 
biallelic expression of IGF2 that efficiently stimulates proliferation of cancer cells. 
 Hypomethylation of retrotransposons also contributes to carcinogenesis via genomic 
instability resulting from insertional mutagenesis and recombination between non-
allelic repeats (Luczak and Jagodzinski, 2006). Long interspersed nuclear elements 
(LINEs) belong to retrotransposons, which are heavily methylated in all cell types in 
mammals. Hypomethylation of LINEs induces transcriptional activation of these 
sequences, which contributes to genomic instability and facilitates tumor 
progression. Hypomethylation of LINEs has been observed in colon cancer and 
chronic lymphocytic leukemia and contributed to the development of malignant 
phenotype of these cells. 
 
3.5.2. Genomic Instability: 
Global hypomethylation causes a global change in chromatin structure by 
promoting chromosomal instability, a hallmark of cancer. This hypothesis is substantiated 
by genetic evidence from mice and humans where mouse embryonic stem cells 
nullizygous for the major DNA methyltransferase (DNMT1) gene exhibited elevated 
mutation rates. DNA hypomethylation has been associated with abnormal chromosomal 
structures in cells from patients suffering from ICF (immunodeficiency, centromeric 
instability and Facial abnormalities) syndrome caused by mutations in DNMT3b (Szyf, 
Page 15 of 40 
 
2003). Hypomethylation is particularly rigorous in pericentromeric satellite sequences, 
and several cancers such as Wilms tumor, ovarian and breast carcinomas  frequently 
contain unbalanced chromosomal translocations with breakpoints in the pericentromeric 
DNA of chromosomes 1 and 16 (Wilson et al., 2007). These unbalanced translocations 
produce loss of heterozygosity (LOH) for markers on chromosome 16, which, in turn, 
strongly correlates with tumour anaplasia. Demethylation of satellite sequences might 
predispose the genome to breakage and recombination (Fig 3). 
 
3.5.3. Insertional Mutagenesis: 
In the event that global hypomethylation occurs in transposable elements it can 
potentially lead to insertional mutagenesis, for example mobilization of LINE L1 
elements has been demonstrated following deletion of DNMT1. Retrotransposon 
insertion may result in alteration of gene expression, disruption of the coding sequences 
and splice sites and deletion of significant target site as well as provide areas of sequence 
identity for both gene conversion and recombination events (Wilson et al., 2007). 
Recently, in an investigation on 50 families with inherited breast cancer three families 
were found to have heritable Alu insertions within the BRCA1 or BRCA2 genes. 
 
3.5.4. Immunological Consequences: 
The most direct link between DNA hypomethylation and immunological 
malfunction is exemplified by the rare recessive disorder, ICF syndrome. Loss of activity 
of DNMT3B is associated with severe immunodeficiency, compromised lymphocyte 
function and with chromosomal rearrangements, mostly localized to the juxtacentromeric 
heterochromatin of chromosomes 1 and 16. Decreased levels of 5 meC and 
methyltransferase activity are seen in the T-cells from patients with active Lupus and 
rheumatoid arthritis. This is linked to decreases in DNMT1 and DNMT3A transcript 
expression, possibly a result of inhibition of the ERK pathway signaling and 
demethylation (Wilson et al., 2007).  The DNA hypomethylation causes over expression 
of the adhesion molecule LFA-1, leading to auto reactivity and eventually autoimmunity. 
In a number of cancers, members of a class of genes normally restricted in expression to 
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testes, the cancer testis antigens (CTA) are found to be hypomethylated and expressed, 
and are immunogenic in cancer patients. These include the XAGE 1 gene in non-small cell 
lung adenocarcinomas, the NY-ESO 1 gene in advanced stage gastric cancer, advanced 
stage (stages III and IV) esophageal cancer and hormone refractory prostate cancers where 
positive reactivity to the antibody correlated with poor survival in patients. 
 
Fig 3. The figure shows how demethylation can lead to chromosomal instability. 
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3.6. Mechanism involved in DNA Demethylation in Cancers: 
DNA methylation pattern is a covalently added epigenetic mark on the DNA which 
provides a cell its identity. Because of the chemical stability of DNA methylation, it has been a 
longstanding accepted belief that the DNA methylation is an irreversible reaction, inherited by a 
semi-conservative methyltransferase and that DNA methylation patterns in mature cell is a 
permanent ―immutable‖ property of somatic cell’s DNA which should not participate in the 
dynamic changes that occur in gene expression programming throughout adulthood (Szyf, 2003). 
This supposed mechanism is however inconsistent with the dramatic changes in DNA 
methylation seen during development and aging or in cancer. Although it has been well 
recognized that during development the DNA methylation pattern is shaped by a series of 
methylation and demethylation events, there has been lack of concrete evidence regarding the 
existence of a DNA demethylase enzyme that catalyzes the demethylation reaction, hence 
passive mechanisms of demethylation has been proposed.  
 
3.6.1. Evidence for Passive Demethylation: 
The passive mechanism of global hypomethylation proposes that demethylation occurs 
when either DNMT1 is absent or occluded from interacting with its substrate during cell division 
by any cytosine analogues (Szyf, 2003). For example: 
 
 According to one model, DNMT1 is excluded from the nucleus during pre-implantation 
stage, a time period which corresponds to a significant loss of 5-methylcytosine in the 
mouse genome. This site-specific demethylation during development is a consequence of 
masking of methylated sites from DNMT1 by tissue specific factors during cell division. 
   
 Recent studies have shown that expression of a bacterial protein with high affinity to its 
recognition element results in demethylation of the element, which supports the 
hypothesis that physical interaction between a transcription factor and the DNA protects 
it from methylation during cell division. However an authentic transcription factor that 
protects a sequence from methylation has not been identified yet.  
 
Page 18 of 40 
 
3.6.2. Mechanism of Passive DNA demethylation in Cancer: 
Genome-wide DNA methylation levels are a product of the balance between mechanisms 
that create and maintain this mark and those that remove it so that any change in this balance 
could lead to a loss of methylation such as that observed in cancer (Wild and Flanagan, 2010). 
DNA hypomethylation could be triggered through the disruption of control in a number of the 
following ways: 
 The lack of DNA methyltransferase (DNMT) activity through knock out of an individual 
DNMT or a combination of DNMTs is linked to genomic hypomethylation and an 
associated chromosomal abnormality and instability (Wild and Flanagan, 2010). 
Decreased DNMT1 expression is associated with genomic hypomethylation and 
increased frequency of certain cancers including T-cell lymphomas and hepatocellular 
adenomas and carcinomas. Mutations in DNMT3B have been linked to hypomethylation 
of the Sat2 tandem repeat in ICF patients. Increased DNMT3B levels in relation to other 
DNMTs have been reported in several cancers (Wilson et al., 2007). These studies all 
highlight that only complete abrogation of function or activity, and not just altered 
expression, are required to induce hypomethylation.  
 
 Passive loss of methylation can also be defined as indirect loss of methylation as a 
consequence of other mechanisms (Wilson et al., 2007). The processes of histone 
modification and chromatin remodeling are intricately involved with DNA methylation in 
establishment of normal epigenetic states and this concerted activity suggests that 
changes to the histone marks may affect the genomic methylation profile and could play a 
role in the induction of hypomethylation (Wild and Flanagan, 2010). For example loss of 
acetylation of H4K16 and increased trimethylation of H4K20 were found to occur at 
repetitive elements such as the Sat2 pericentromeric repeat as well as subtelomeric D4Z4 
and NBL2 repeats and correlated with hypomethylation of these regions in cancers 
compared to normal controls. These data provide a hypothesis that DNA 
hypomethylation could result due to a cascade of epigenetic alterations starting with 
histone modifying enzymes.  
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 Another hypothesis that supports passive loss of methylation is ―diverted 
methyltransferase activity‖. This hypothesis suggests that genome wide hypomethylation 
can be a consequence of the high affinity of DNA methyltransferases to sites of DNA 
damage (such as strand breaks, gaps, abasic sites and uracil) (Wild and Flanagan, 2010) 
which sequesters the available methyltransferases from lesion-free DNA to promote 
passive replication-dependent demethylation. 
  
 Lastly, the ―metabolic hypothesis‖ of hypomethylation suggests that the demethylation 
results from a cellular deficiency in the methyl donor S-adenosyl methionine (SAM). 
Combined genetic variation in key metabolic enzymes and deficiency of essential 
nutrients such as methionine, choline, folic acid and vitamin B12 can all result in aberrant 
methylation due to inefficient metabolism (Patra et al., 2003). 
 
3.6.3. Evidence for Active Demethylation: 
There is a long list of  well documented data supporting the hypothesis that active 
demethylation of the genome in takes place during differentiation and development (Szyf, 2003). 
For example,  
 Induction of a lytic EBV viral cycle in some B cell lymphomas is associated with 
replication independent global demethylation. 
 Global loss in methylated cytosine is seen in paternal genome within hours of cell 
fertilization before the start of the fist cell division in order to allow appropriate 
imprinting of gametes and the early embryo. 
 Following fertilization, the male pronucleus undergoes vast modifications, including 
replacement of protamines with histones and genomic DNA demethylation. 
 The first exon of myogenin is demethylated within minutes after initiation of the 
differentiation of C2C12 cells into myotubules.  
 Active demethylation has also previously been observed in the muscle specific α-actin 
gene upon differentiation. 
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3.6.4. Mechanism involved in Active DNA demethylation in Cancer: 
Several mechanisms and enzymatic activities were proposed to be responsible for active 
demethylation of the genome, although no concrete theory has been accepted till date. A reaction 
that truly reverses the DNA methylation must involve breakage of the bond between the methyl 
residue and cytosine ring, release of this methyl group as a monocarbon compound and 
regeneration of the cytosine base in DNA with an addition of hydrogen at the same position 
(Szyf, 2003). However it was the general idea that this reaction is not feasible because of the 
inherent difficulty in an enzymatic cleavage of this carbon–carbon bond which is highly 
thermodynamically stable (Patra, et al., 2008). Therefore, alternative mechanisms which were 
variations on the concept of passive demethylation and bypassed this difficulty were proposed. 
The main problem with the original passive demethylation model was that it requires cell 
division for introduction of unmethylated cytosines, although documented evidence for 
demethylation in absence of DNA replication were present. The modified models of active 
demethylation therefore proposed that a repair process introduced new unmethylated cytosines to 
replace the methylated cytosines, a process that could occur even in the absence of cell division. 
The first model for active demethylation proposes that a repair based mechanism where 
glycosylase cleaves the bond between the methylated cytosine base and the deoxyribose sugar 
leaving an abasic ribose in DNA which is then repaired by nuclear repair mechanisms (Szyf, 
2003) (Fig 4). This mechanism is based on biochemical reactions that are known to exist and 
does not involve any novel activities.  
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Fig 4. The figure shows active demethylation model (Adapted from Patra, et al., 2008). 
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3.7. The Demethylase Dilemma: 
The main problem with both passive and active demethylation hypotheses discussed 
above is that whereas they can provide an attractive mechanism for site-specific demethylation, 
they do not seem to satisfy the criteria that such mechanisms are possibly involved in genome 
wide demethylation that occurs during early development. Since both mechanisms involve 
removal of the 
methyl
cytosine by a process involving DNA damage followed by repair, there may 
be a chance that global demethylation by either mechanism would result in genome wide damage 
to DNA which might seriously hamper the integrity of the genome at a critical time point early in 
development (Szyf, 2003). Therefore a different prospective to the question of active 
demethylation was considered. It was postulated that demethylation occurs by a true reversal of 
the DNA methylation reaction where a demethylase must catalyze the release of a methyl group 
from DNA to transform the methylated cytosine to an unmethylated form just as a 
methyltransferase catalyze the covalent addition of a methyl group to an unmethylated cytosine 
to form methyl cytosine (Patra et al., 2003). Several studies carried out for the discovery of a 
demethylase has resulted in the following evidences:    
 A putative demethylase activity was found out from human lung carcinoma cell line 
A549 that reverses the DNA methylation reaction and releases the methyl moiety in the 
form of methanol. 
 
 Studies showed that a shorter isoform of the methyl binding protein MBD2, MBD2b 
catalyzed active demethylation of DNA in vitro. However, the identification of MBD2b 
as a demethylase was disputed by a number of groups who showed that MBD2 was 
associated with a repressor complex NurD and was a component of the methylated DNA 
repression complex MeCP1.These groups did not get the same results for demethylase 
activity of MBD2 in vitro. In addition, mbd2−/− mice were shown not to be defective in 
their DNA methylation pattern and post fertilization global demethylation of the paternal 
genome was shown to proceed without hindrance in mbd2−/− mice. 
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 Putative demethylase activity was also observed in several studies of nuclear and whole 
cell extracts, including a protease-sensitive activity in murine erythroleukemia nuclear 
extracts and RNase sensitive activity in whole cell rat myoblast extracts (Wild and 
Flanagan, 2010). 
 
 Two studies of estrogen receptor-alpha responsive genes in cultured breast cancer cells 
noted cyclical patterns of demethylation and remethylation of CpG sites in target genes 
over a 2-hr period following treatment with estrogen (Wild and Flanagan, 2010). Through 
chromatin immunoprecipitation studies it was demonstrated that recruitment of 
DNMT3A and DNMT3B to the promoter regions of these genes may be involved in the 
demethylation process (Ooi and Bestor, 2008) (Fig 5). It was suggested that the 
deaminase activity of these enzymes may allow them to mediate oxidative deamination of 
methylcytosine in the absence of the methyl donor SAM (S-adenosine L-methionine) 
converting the methylcytosine to a thymine residue, and leading to a guanine: thymine 
(G: T) mismatch, and subsequent removal of the thymine by thymine DNA glycosylase 
(TDG) and methyl-binding protein 4 (MBD4). Finally, the abasic site is repaired by the 
base excision repair mechanisms, ultimately replacing the methylated cytosine residue 
with an unmethylated counterpart. 
 
  Finally, studies in both Xenopus and Zebra fish have suggested that the nuclear protein 
Gadd45a may be involved in DNA demethylation via a base excision repair mechanism. 
GADD45a is specifically recruited to the Oct4 gene during active demethylation of this 
region in Xenopus oocytes. Similar experiments in Zebra fish revealed a demethylase 
activity dependent on the 5-methylcytosine deaminase AICDA (AID), the G: T mismatch 
repair enzyme MBD4 and GADD45a (Rai, et al., 2008) (Fig 6). It was suggested that a 
demethylation mechanism similar to that described above, whereby methylcytosine is 
first deaminated to thymine by AID, followed by base excision repair to cytosine by 
MBD4 and GADD45a. 
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Fig  5. The figure shows active demethylation mediated by DNMT3a and DNMT3b in mammals 
and its comparison with established pattern in plant (Ooi and Bestor, 2008). 
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Fig 6. The figure shows the mechanism of demethylation mediated by nuclear protein GADD45 
in Zebra fish (Rai, et al., 2008). 
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In summary, despite the fact that the characterization of proteins such as MBD2 and 
GADD45a as a candidate demethylase is still uncertain and controversial, these recent studies 
open up the possibility that DNA methylation is a reversible biological modification (Szyf, 
2003). Further research regarding the activity of these proteins in tumor versus normal tissues 
might address the problem and may subsequently lead to the discovery of a DNA demethylase. 
Alternatively, if these particular proteins are not involved in cancer specific genome-wide 
hypomethylation and alternative candidates might be sought (Wild and Flanagan, 2010). 
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RATIONALE BEHIND THE PROJECT 
DNA methylation and DNA demethylation are two distinct, exactly opposite, 
conceptually defined chemical reactions (similar to other epigenetic modifications such as 
acetylation and deacetylation, phosphorylation and dephosphorylation, which are frequently 
encountered while studying the dynamics of the epigenome. 
Hence, it is hypothised that if there exists an enzyme that can covalently attach -CH3 
group to the cytosine base of DNA at 5-carbon position, there must surely exist another putative 
enzyme that must show the ability to remove the -CH3 group from the methylated cytosine base.  
Keeping this hypothesis in mind and based on the literature survey, the present work has 
been undertaken to investigate if two candidate proteins MBD2 and MBD4 have putative 
demethylase activity in vitro. The objectives of the project include: 
 Comparative qualitative analysis of the expression level of Methyl Binding proteins – 
MBD1, MBD2, MBD3 and MBD4 in normal and cancerous tissue. 
 Comparison of the expression level of the MBD2 and MBD4 in both normal and 
cancer tissues with that of GADD45, a putative DNA demethylase found in Zebra fish 
in order to  determine if MBD2 and MBD4 can have DNA demethylase activity. 
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MATERIALS AND METHODS 
1. Collection of Samples: 
        Blood was collected as the normal tissue from the local CWS Hospital, Rourkela, Odisha, stored in 
ice and immediately processed for better RNA extraction.  Cancer tissue (Lymph Node Carcinoma) was 
collected from National Medical College, Kolkata and stored in RNA later (Sigma) at –200C until the 
extraction of RNA. 
2. Extraction of Total RNA: 
Total RNA was extracted from both blood (normal) and cancer tissue using GeneJET
TM 
RNA Purification Kit (Fermentas). 
2.1. Extraction from Blood: 
The collected blood was centrifuged at 3000 rpm for 15 mins at 4° C. The supernatant 
containing the serum was separated from the pellet which contains the blood cells. The pellet 
was resuspended in 600 μl of Lysis Buffer (supplemented with 20 μl of 14.3 M β-
mercaptoethanol for every 1ml of Lysis Buffer) and vortexed to mix thoroughly. 450 μl of 
ethanol (96-100%) was mixed with the solution. About 700 μl of the lysate was transferred to a 
GeneJET
TM 
RNA Purification Column inserted in a collection tube and centrifuged at 12000 rpm 
for 1 min at 4° C. The flow-through was discarded and the column was placed into a new 2 ml 
RNase-free microcentrifuge tube. 700 μl of Wash Buffer 1(supplemented with 250 μl of ethanol 
for every 1ml Wash buffer 1) was added to the column and centrifuged for 1 min at 12000 rpm. 
The flow-through was discarded and 600 μl of Wash Buffer 2 (supplemented with 850 μl of 
ethanol for every 0.5 μl Wash buffer 2) was added to the column. It was centrifuged at 12000 
rpm for 1 min at 4° C. The flow-through was again discarded. Centrifugation was again done at 
12000 rpm for 1 min at 4 ° C by adding 250 μl of Wash buffer 2. The flow-through was 
discarded and the column was transferred to a sterile 1.5 RNase-free microcentrifuge tube. 100 
μl of nuclease-free water was added to the column and centrifuged for 1 min at 12000 rpm to 
elute RNA. The RNA was stored at - 20° C for further use or immediately processed for cDNA 
synthesis. 
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2.2. Extraction from Cancer tissue: 
About 30 mg of frozen cancer tissue was taken and thoroughly homogenized using Lysis 
buffer. The grinded tissue was transferred into a sterile 2 ml microcentrifuge tube containing 300 
μl of Lysis Buffer (supplemented with 20 μl of 14.3 M β-mercaptoethanol for every 1ml of Lysis 
Buffer). The mixture was vortexed for 10 secs for thorough mixing. The next steps of extraction 
were same as that followed in the previous protocol for blood RNA extraction. 
3. Quantitative Estimation of RNA Concentration by Spectrophotometric 
Analysis: 
The concentration of the extracted total RNA from both blood and cancer tissue was 
quantified by measuring the absorbance at 260 nm in a spectrophotometer (ELICO, BL 200 Bio 
Spectrophotometer, double beam) and calculated by using the formula as given below: 
Total RNA (μg /ml) = OD260 × 40 × Dilution factor. 
4. Quantitative Estimation of RNA Concentration by Denaturing Gel   
Electrophoresis: 
 
The extracted RNA from both blood and cancer tissue was run on a denaturing agarose 
gel and the quantity of RNA estimated from the band intensity. For denaturation gel (40 ml), 0.6 
g agarose (Sigma), 28.8 ml dH2O (Sigma), 7.2 ml formaldehyde (Sigma), 4 ml 10X MOPS 
buffer were mixed properly. About 2 μl (2μg) of the total RNA was mixed with 18 μl 1X 
Reaction Buffer (2μl of 10X MOPS Buffer, 4 μl formaldehyde, 10 μl formamide (Sigma) ,2 μl 
0.2 mg/ml Etbr (Sigma)) and incubated at 55 °C for 1 hr. It was then cooled on ice and loaded in 
the wells of the denaturing gel. 
 
5. First strand cDNA synthesis: 
Total RNA (4 g) from both blood and cancer tissue were used for first strand cDNA 
synthesis by reverse transcription using RevertAid
TM 
First Strand cDNA Synthesis Kit 
(Fermentas) in a thermocycler (Biorad). The RNA were incubated with 1 l of oligo(dT)18  
primers (100 μM, 0.2 μg/μl) and 12 μl of nuclease-free water at 65 C for 5 min. The reaction  
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was cooled on ice to allow the primers to anneal to the RNA, then spin down and placed on ice 
again after which the following components were added to the reaction in order; 4 l of 5X 
Reaction Buffer, 1 l of Ribolock
TM
 RNase inhibitor (20 U/ l), 2 l of 10 mM dNTPs and 1.0 
L of RevertAid
TM
 M-MuLV-Reverse Transcriptase (200 U/ l). The reagents were gently mixed 
and incubated for 1 hr at 42 C. Heating at 70 C for 5 min terminated the reaction and the 
synthesized cDNA was stored at –20 0 C for further use. 
6. Gene-specific PCR for amplification of the desired gene: 
6.1. Primers selection: 
A set of specific forward and reverse primers for the amplification of the desired gene 
under study was selected from published papers (Patra et al., 2003; Zou et al., 2002). The cDNA 
of both the blood and cancer tissue synthesized were used as the template for the specific 
primers. The constitutively expressed housekeeping gene, β-actin was used as a positive control 
to ensure high quality. The primer sequences used for the PCR reaction are shown in Table 1: 
Table 1.Table showing the sequence of the forward and backward primers used. 
 
 
 
PRIMER TYPE SEQUENCE 
 
MBD1 
Forward    5’ CACCCTCTTCGACTTCAAACAAG  3’ 
Reverse             5’ CAACCTGACGTTTCCGAGTCTT  3’ 
 
MBD2 
Forward 5’ AACCCTGCTGTTTGGCTTAAC  3’ 
Reverse 5’ CGTACTTGCTGTACTCGCTCTTC  3’ 
 
MBD3 
Forward  5’  CCGCTCTCCTTCAGTAAATGTAAC  3’ 
Reverse   5’ GGCTGGAGTTTGGTTTTCAGAA  3’ 
 
MBD4 
Forward    5’ TGGTGGTGCATGCCTGTAAT  3’ 
Reverse             5’ TGAGACAGGGTCTCTCTCTGTCAT  3’ 
 
GADD45 
Forward             5’ GCTCTCTCCCTGGGCGACCTG  3’ 
Reverse             5’ CCATGTAGCGACTTTCCCGGC  3’ 
 
β-ACTIN 
Forward             5’  TCTACAATGAGCTGCGTGTG  3’ 
Reverse 5’  TCTCCTTCTGCATCCTGTC  3’ 
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6.2. PCR conditions: 
 
The PCR sample mixtures, in a 25 μl volume, contained 17 μl of dH2O (Sigma), 2.5 μl of 1X 
PCR buffer (Sigma), 0.5 μl of dNTP (0.2 mM, Sigma), 1.5 μl of MgCl2 (1.5 mM, Sigma), 0.5 μl 
each of the forward and reverse primers (0.2 μM, Sigma) of MBD1, MBD2, MBD3, MBD4 and 
GADD45 and 0.5 μl Taq DNA-polymerase (1U/μl, Himedia). 2 μl of each cDNA sample was 
added. PCR amplifications of MBD1, MBD2, MBD3 and MBD4 were performed in a thermal 
cycler by initial denaturation at 94° C for 1 min, followed by 30 cycles of denaturation at 94° C  
for 20 secs, annealing at 57 ° C for 20 secs, and extension at 72° C for 30 secs, followed by an 
final extension step at 72° C for 5 mins. For amplification of GADD45, the following conditions 
were followed: initial denaturation at 95° C for 5 mins, prior to 30 cycles of denaturation at 94° 
C for 30 secs, annealing at 57 ° C for 20 secs, and extension at 72° C for 45 secs, followed by an 
final extension step at 72° C for 10 mins. 
7. Agarose Gel Electrophoresis of the PCR products: 
The generated PCR products were analyzed by electrophoresis on 1.5% agarose gel. 
Agarose gel was prepared with 1X TAE (Tris Acetate EDTA, Sigma) buffer. Before casting 
0.1% ethidium bromide was added to the gel. 15 μl of sample (PCR product) was loaded to each 
well along with 3 μl 1 X loading dye. 5 μl of DNA marker (1 kb, Sigma). The gel was run in 
TAE buffer at 100 volt for 40 minutes. 
8. Analysis of the Relative Expression level of the different genes:  
The relative levels of expression of each gene were analyzed by taking the absorbance 
through spectrophotometric readings. The ratios of desired genes/β-actin product were 
subsequently calculated after subtraction of the background pixel intensity for each gene of 
interest and used to assess the differences in expression levels between normal and cancer tissue. 
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RESULTS AND DISCUSSION 
1. Quality Check of RNA Isolated from Normal And Cancer  Samples: 
The concentration of the extracted total RNA from normal tissue and cancer tissue was 
estimated by taking OD260nm/OD280nm, which was found to be 572 μg/ml for normal tissue and 
409 μg/ml for cancer tissue and then run on gel (Fig 7 & 8). Further integrity of the RNA 
samples was checked by RT-PCR using β-Actin primer pairs. Strong amplification products of 
β-Actin was found for all the genes in both normal and cancer tissue. 
 
 
 
 
 
 
Fig 7. The gel photograph of total RNA extracted in 1% agarose gel. 
 
 
 
 
 
 
 
Fig 8. The gel photograph of total RNA extracted from (A) blood and (B) cancer tissue run in 
1.5% denaturing gel. 
(B) (A) 
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2. Gene Specific Amplification: 
The PCR products obtained by gene specific amplification were run in a 1.5% agarose 
gel ( Fig 9) and the concentration was estimated by spectrophotometric reading. The results 
obtained are given below. The expression of β-actin (682 bp) proves the integrity of the RNA 
extracted. 
 
                        
Fig 9. The gel photograph of the different genes in cancer tissue after gene-specific amplification 
seen in a 1.5% agarose gel. 
The gene expression of MBD1, MBD2, MBD3, MBD4, and GAdd45 in blood and lymph 
node carcinoma tissue were analyzed. MBD1 is a transcriptional repressor characterized by two 
or three CXXC domains that bind methylated CpG islands of the tumor suppressors p16, VHL, 
and E-cadherin genes.. MBD2 has been reported to possess DNA (cytosine-5) demethylase 
activity along with repressor function. MBD4 is a repair enzyme of the DNA-glycosylase family 
and MBD3 apparently lacks specific methylated DNA-binding capability although it has a high 
degree of sequence similarity with MBD2. 
     1        2       3      4       5           6             7 
LANE 5 – MARKER  
   (1.5 kb) 
LANE 6 – β-ACTIN 
LANE 1 - MBD1 
LANE 2 - MBD2 
LANE 3 - MBD3 
LANE 4 - MBD4 
LANE 7 – GADD45 
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From the present study, the expression of MBD1, MBD2, MBD3 and GADD45 was 
seen. It can be said that while MBD1 (125 bp), MBD2 (101 bp), MBD3 (101 bp) and GADD45 
(492 bp) were expressed in cancer tissue, MBD4 was not expressed. The band intensity of 
GADD45 is much more than MBD proteins which might point towards more demethylation 
activity by GADD45 by a repair based mechanism. It can be thus considered that Lymph node 
carcinoma tissue shows demethylation activity through DNA repair mechanism mediated by 
GADD45. Expression of MBD2 might point towards a suspected demethylase activity. 
 
 
Fig 10.The gel photograph showing the different genes from cancer tissue in different lanes1-
MBD1, 2-MBD2, 3-MBD3, 4-MBD4, 5-MARKER, 6-β-ACTIN, 7- GADD45, 8-EZH2, 9-
DNMT3A, 10- DNMT3B, 11- P53, 12- P53i, 13- DNMT1. 
On investigating the expression of other epigenetically modulating genes (fig 10) like 
DNMT1, DNMT3A, DNMT3B, HDAC, P300, P53, P53i, EZH2 and G9A, it can be seen that the 
DNA methyltransferases DNMT1 is not expressed while DNMT3A and DNMT3B are expressed 
which points to the fact that that maintenance methylation by DNMT1 might be absent in the 
cancer tissue which represents one mechanism of passive demethylation. Similarly Histone 
methyltransferase G9A is not expressed whereas EZH2 shows very less expression. This shows 
that loss of histone lysine methylation promotes demethylation activity and thus substantiates the 
claim that Lymph node carcinoma shows extensive demethylation activity. 
    1     2       3      4      5       6       7           8       9     10      11      12      13 
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3. Expression analysis of the desired genes: 
After the gene-specific amplification of the given genes was done for both blood and 
cancer tissue, the concentration was checked by taking its OD260/280 in spectrophotometer. The 
following results were obtained (Table 2) and the data was plotted in the form of graph to do a 
comparative analysis of the expression level of the different genes.  
 Table 2.The table shows the concentrations of PCR products after gene-specific amplification. 
 
Gene 
 
Concentration (μg/ml) at 
260/280 nm normal tissue 
 
Concentration (μg/ml) at 
260/280 nm cancer tissue 
DNMT1 1369 1472 
DNMT3A 1158 1262 
DNMT3B 1267 1768 
MBD1 1536 1786 
MBD2 1154 1238 
MBD3 1098 1435 
MBD4 1286 1684 
GADD45 1673 1764 
G9A 1734 1828 
EZH2 1369 1416 
HDAC 1732 1746 
P300 1543 1864 
P53 1358 1474 
P53I 1569 1440 
β-actin 1745 1882 
 
The graphs were plotted (Fig 11,12,13,14) according to the data given above and the 
following results were obtained.GADD45 showed the highest expression in comparison to the β-
actin gene which is a constitutively expressed house-keeping gene which indicates that the 
cancer tissue shows increased demethylation activity. 
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Fig 11. Graph showing comparative study of expression level of the genes under study (MBD1, 
MBD2, MBD3, MBD4 and GADD45 as well as β-actin in both normal & cancer tissue. 
 
 
Fig 12. Graph showing comparative study of expression level of the genes under study (MBD1, 
MBD2, MBD3, MBD4 and GADD45 with that of β-actin in both normal & cancer tissue. 
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Fig 13. Graph showing comparative study of expression level of the all genes under study (genes 
involved in epigenetic regulation) as well as β-actin in both normal & cancer tissue. 
 
Fig 14. Graph showing comparative study of expression level of the all genes under study (genes 
involved in epigenetic regulation) with that of β-actin in both normal & cancer tissue. 
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CONCLUSION 
The project provides us an insight into the possible mechanisms of DNA demethylation 
in lymph node cancer. From the results it is clear that increased hypomethylation observed in 
lymph node carcinoma may be mediated by GADD45. It is generally assumed that passive loss 
of methylation is the most likely mechanism of global demethylation as the mechanism of active 
DNA demethylation in mammal cells has been difficult to define. The prevailing view in the 
academic arena favors a slow loss of methylation as a consequence of other oncogenic changes. 
The continued search for DNA demethylases therefore must continue in order to identify the 
critical proteins that are involved in active demethylation. If these proteins are identified and 
their demethylase activity proved beyond doubt, then functional investigations of putative active 
mechanisms of hypomethylation in cancer can be also conducted. Further studies into the 
mechanism and consequences of oncogenic mutations, would be useful to determine if 
hypomethylation is a consequence of cancer initiation event or its cause. Continued investigation 
of putative active demethylation complexes will remain important until this mechanism is fully 
elucidated. Finally, long-term follow up treatment of patients with demethylating agents such as 
decitabine can provide insight into a very important question of whether DNA hypomethylation 
alone can initiate new tumors in humans or whether there is involvement of others factors also. 
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